ARDIAN invests in IVB Wellness Lab

Announced in January 2026, the definitive agreement entered into by Ardian Growth to acquire a minority stake in IVB Wellness Lab establishes a joint ownership consortium alongside the target's founders and historical shareholder Label Capital. Under the structured minority growth recapitalization, co-founders Dr. Isabel Viña Bas, Valerio Soto Ferri, and Carlos Viña Bas maintain their operational executive leadership roles alongside their equity ownership to steer the company's next expansion cycle. Paris-based growth equity firm Label Capital, having initially invested in the business, remains an active minority partner within the shareholding consortium. From a strategic perspective, the entry of the private equity sponsor aims to allocate institutional expansion capital to accelerate the brand's omnichannel penetration beyond its core Spanish retail pharmacy footprint into broader European distribution corridors. Additionally, the strategic roadmap focuses on scaling proprietary data-driven direct-to-consumer (D2C) marketing channels, bolstering the laboratory's ongoing medical R&D formulations, and supporting new clinical validation studies across specialized metabolic wellness lines. The transaction mobilized an advisory syndicate spanning corporate, financial, and strategic due diligence scopes across Spain and France. On the buy-side, Ardian engaged Garrigues Madrid for corporate legal structuring, while Eight Advisory conducted financial, legal, labor, and tax due diligence audits, and Digital Value managed strategic due diligence reviews. For the selling and target entities, IVB Wellness Lab was advised by Alvarez & Marsal on financial advisory alongside Garrigues Valencia for legal counsel. Label Capital retained White & Case, Mayer Brown, and EY Abogados as corporate legal advisors. Subject to customary completion requirements, transaction closing is scheduled for the first quarter of 2026.